The DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.
Medication Usage and the Risk of Neoplasia in Patients With Barrett's Esophagus
Open accessAbstract
Background & aims Experimental evidence indicates that proton pump inhibitors (PPIs), nonsteroidal anti-inflammatory drugs (NSAIDs)/aspirin, and statins can protect patients with Barrett's esophagus (BE) from developing neoplasias. However, only limited data are available on chemoprevention in patients with BE.Methods A retrospective observational study was performed using data from patients with documented BE. Prescription information was collected from pharmacy records. Cox regression analyses were performed to examine the association between prescriptions for PPIs, NSAIDs/aspirin, or statins and the risk of developing esophageal dysplasia or adenocarcinoma during follow-up (from 1982 to 2005).Results We examined 344 patients diagnosed with BE (mean age 61 years, 90.4% Caucasian, 94.2% male). After BE diagnosis, 67.2% of the patients were prescribed PPIs for a mean duration of 5.1 years; 49.1% were prescribed NSAIDs for a mean duration of 3.6 years, and 25.3% were prescribed statins for a mean duration of 2.8 years. During 2620 patient-years, high grade dysplasia or esophageal adenocarcinoma developed in 33 patients. PPI treatment after BE diagnosis was associated with a reduced risk of high grade dysplasia or cancer; this association persisted after adjustment for gender, age, and the length of BE. NSAID and/or aspirin therapy were associated with a nonsignificant trend toward lower incidence of high grade dysplasia or esophageal cancer.Conclusions PPI therapy reduces the risk of neoplasms in patients with BE. NSAIDs/aspirin appear to reduce cancer risk whereas statin use is not significantly associated with the risk of neoplasia in patients with BE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“because their long-term use significantly decreases the risk of the progression to high-grade dysplasia and EAC[50-52]”
From Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified (2019) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma
Lagergren, J., Bergström, R., Lindgren, A., & Nyrén, O. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903183401101 · Cited by 3,012
Wilkinson, E. (2002) · Nature Cell Biology · doi:10.1016/s1470-2045(02)00737-4 · Cited by 951
Corley, D. A., Kerlikowske, K. M., Verma, R., & Buffler, P. A. (2003) · Gastroenterology · doi:10.1053/gast.2003.50008 · Cited by 524
Chow, W.-H. (1995) · JAMA · doi:10.1001/jama.1995.03530060048032 · Cited by 376
Buttar, N. S., Wang, K. K., Leontovich, O. N., Westcott, J. Y., Pacifico, R. J., Anderson, M. A., Krishnadath, K. K., Lutzke, L. S., & Burgart, L. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.32371 · Cited by 346
Proton Pump Inhibitors Are Associated with Reduced Incidence of Dysplasia in Barrett's Esophagus
El‐Serag, H. B., Aguirre, T. V., Davis, S., Kuebeler, M. K., Bhattacharyya, A., & Sampliner, R. E. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.30228.x · Cited by 329
Self-citation3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the Risk of Cancer
Blais, L., Desgagné, A., & LeLorier, J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.15.2363 · Cited by 326
Cyclooxygenase-2 Expression in The Barrettʼs Metaplasia–Dysplasia–Adenocarcinoma Sequence
Morris, C. D., Armstrong, G. R., Bigley, G., Green, H. E., & Attwood, S. E. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03599.x · Cited by 250
Vaughan, T. L., Dong, L. M., Blount, P. L., Ayub, K., Odze, R. D., Sanchez, C. A., Rabinovitch, P. S., & Reid, B. J. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70431-9 · Cited by 216
Proton‐pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus
Hillman, L. C., Chiragakis, L., Kaye, G., Clarke, A. C., & Shadbolt, B. (2004) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2004.tb05991.x · Cited by 194
Secondary Chemoprevention of Barrett's Esophagus With Celecoxib: Results of a Randomized Trial
Heath, E. I., Canto, M. I., Piantadosi, S., Montgomery, E. A., Weinstein, W. M., Herman, J. G., Dannenberg, A. J., Yang, V. W., Shar, A. O., Hawk, E. T., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk112 · Cited by 178
Karp, I., Behlouli, H., LeLorier, J., & Pilote, L. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.12.011 · Cited by 152
Statins Inhibit Proliferation and Induce Apoptosis in Barrett's Esophageal Adenocarcinoma Cells
Ogunwobi, O. O., & Beales, I. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01773.x · Cited by 147
Cooper, B. T., Chapman, W., Neumann, C. S., & Gearty, J. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02825.x · Cited by 109
Pera, M. (2003) · World Journal of Surgery · doi:10.1007/s00268-003-7052-2 · Cited by 96
Aspirin, Nonsteroidal Anti-inflammatory Drugs, and the Risks of Cancers of the Esophagus
Sadeghi, S., Bain, C. J., Pandeya, N., Webb, P. M., Green, A. C., Whiteman, D. C., & Study, F. T. A. C. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-2852 · Cited by 79
Barrett's Esophagus and Medications that Relax the Lower Esophageal Sphincter
Corley, D. A., Levin, T. R., Habel, L. A., & Buffler, P. A. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00539.x · Cited by 54
Tsibouris, P., Hendrickse, M. T., & Isaacs, P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02150.x · Cited by 28
Barrett's oesophagus and proton pump inhibitors: a pathological perspective
Shepherd, N. A. (2000) · Gut · doi:10.1136/gut.46.2.147 · Cited by 16
Flagged first, then by citations
1 of the 20 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus
Shaheen, N. J., Falk, G. W., Iyer, P. G., & Gerson, L. B. (2015) · The American Journal of Gastroenterology · doi:10.1038/ajg.2015.322 · Cited by 1,498
“Similarly, in patients with T1a or T1b sm1 EAC and unfavorable prognostic factors, such as poor diff erentiation or lymphovascular invasion, surgical consultation should be obtained. ter.”
Fitzgerald, R. C., di Pietro, M., Ragunath, K., Ang, Y. S., Kang, J.-Y., Watson, P. J., Trudgill, N. J., Patel, P., Kaye, P., Sanders, S., et al. (2013) · Gut · doi:10.1136/gutjnl-2013-305372 · Cited by 1,344
Rustgi, A. K., & El‐Serag, H. B. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1314530 · Cited by 1,318
Self-citationSmyth, E. C., Lagergren, J., Fitzgerald, R. C., Lordick, F., Shah, M. A., Lagergren, P., & Cunningham, D. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.48 · Cited by 1,077
American Gastroenterological Association Technical Review on the Management of Barrett's Esophagus
Spechler, S. J., Sharma, P., Souza, R. F., Inadomi, J. M., & Shaheen, N. J. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.031 · Cited by 1,054
Metadata
- Authors
- Nguyen, D. M., El-Serag, H. B., Henderson, L., Stein, D., Bhattacharyya, A., & Sampliner, R. E.
- Affiliations
- Michael E. DeBakey VA Medical Center (US)
- University of Arizona (US)
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2009-12
- Volume
- 7
- Issue
- 12
- Pages
- 1299-1304
- ISSN
- 1542-3565 (ISSN-L)
- PMC
- PMC2789910
- OpenAlex
- W2071302779
- Cited by
- 159
- References
- 20
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 7 · 2022: 4 · 2021: 13 · 2020: 4 · 2019: 8 · 2018: 4 · 2017: 9 · 2016: 4 · 2015: 15 · 2014: 15 · 2013: 17 · 2012: 25
- FWCI
- 18.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Gastroenterology and Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA116845)
- National Institute of Diabetes and Digestive and Kidney Diseases (K24DK078154, DK 563338)
- Topics
- Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
- Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
- Health Sciences › Medicine › Surgery › Esophageal and GI Pathology
- Keywords
- Barrett's esophagus, proton pump inhibitors, nonsteroidal anti-inflammatory drugs, aspirin, statins, chemoprevention, esophageal adenocarcinoma, high-grade dysplasia, neoplasia risk, medication use
- MeSH terms
- Aged, Anti-Inflammatory Agents, Non-Steroidal, Barrett Esophagus, Esophageal Neoplasms, Female, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Drug Monitoring, Proton Pump Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
